Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. In clinical trials, signi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peggy Soule Odegard, Anthony DeSantis
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/580c28e1c70f44b4bc520906bd7dbdfa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:580c28e1c70f44b4bc520906bd7dbdfa
record_format	dspace
spelling	oai:doaj.org-article:580c28e1c70f44b4bc520906bd7dbdfa2021-12-02T04:24:42ZRecent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes1178-7007https://doaj.org/article/580c28e1c70f44b4bc520906bd7dbdfa2009-07-01T00:00:00Zhttp://www.dovepress.com/recent-results-of-exenatide-use-as-adjunctive-therapy-in-the-treatment-a3392https://doaj.org/toc/1178-7007Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. In clinical trials, significant reductions in serum glucose and weight were demonstrated for exenatide with primary glycemic effects of the twice daily formulation on prandial glucose control. In this paper, we review recent research with exenatide as adjunctive therapy in type 2 diabetes mellitus. In particular, studies demonstrate ongoing benefit on glycemic control and weight reduction with continued therapy up to 82 weeks duration and efficacy as adjunctive therapy for patients taking metformin, thiazolidinediones, and/or a sulfonylurea and as compared to sitagliptin and various insulin formulations. Compared to insulin, exenatide likely has greatest benefit for those patients who are overweight or who need improved prandial glucose control. The new long-acting release formulation of exenatide has demonstrated slightly improved efficacy compared to the twice daily formulation as well as a reduction in gastrointestinal side effects. Emerging research is further exploring novel benefits of exenatide as adjunctive DM therapy, effects on prandial glycemic control, markers of hepatic inflammation, alternative dosage forms including intra-nasal administration, and effects on beta cell function.Keywords: exenatide, diabetes, GLP-1 Peggy Soule OdegardAnthony DeSantisDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 135-144 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Peggy Soule Odegard Anthony DeSantis Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
description	Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. In clinical trials, significant reductions in serum glucose and weight were demonstrated for exenatide with primary glycemic effects of the twice daily formulation on prandial glucose control. In this paper, we review recent research with exenatide as adjunctive therapy in type 2 diabetes mellitus. In particular, studies demonstrate ongoing benefit on glycemic control and weight reduction with continued therapy up to 82 weeks duration and efficacy as adjunctive therapy for patients taking metformin, thiazolidinediones, and/or a sulfonylurea and as compared to sitagliptin and various insulin formulations. Compared to insulin, exenatide likely has greatest benefit for those patients who are overweight or who need improved prandial glucose control. The new long-acting release formulation of exenatide has demonstrated slightly improved efficacy compared to the twice daily formulation as well as a reduction in gastrointestinal side effects. Emerging research is further exploring novel benefits of exenatide as adjunctive DM therapy, effects on prandial glycemic control, markers of hepatic inflammation, alternative dosage forms including intra-nasal administration, and effects on beta cell function.Keywords: exenatide, diabetes, GLP-1
format	article
author	Peggy Soule Odegard Anthony DeSantis
author_facet	Peggy Soule Odegard Anthony DeSantis
author_sort	Peggy Soule Odegard
title	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
title_short	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
title_full	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
title_fullStr	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
title_full_unstemmed	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
title_sort	recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/580c28e1c70f44b4bc520906bd7dbdfa
work_keys_str_mv	AT peggysouleodegard recentresultsofexenatideuseasadjunctivetherapyinthetreatmentofpatientswithtype2diabetes AT anthonydesantis recentresultsofexenatideuseasadjunctivetherapyinthetreatmentofpatientswithtype2diabetes
_version_	1718401245504339968

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

Ejemplares similares